Condition
Cardiovascular Outcomes
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Completed3
Unknown2
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04125212UnknownPrimary
Air Pollution and Cardio-metabolic Health
NCT01921010Phase 4CompletedPrimary
Benefit of Elevation of HDL-C in Women
NCT03899675Not ApplicableCompleted
Impact of Caffeine Intake on Autonomic Parameters in the Exercise of Strength
NCT02601352CompletedPrimary
Air Pollution and Cardiometabolic Study
NCT03206593Unknown
Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure
NCT02058875Phase 4Withdrawn
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
Showing all 6 trials